Drugs / 68Ga-Pentixafor
68Ga-Pentixafor
Trials 16 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT07007325 | Sep 2026 → Sep 2028 expected | small cell lung carcinoma | Institut Cancerologie de l'Ouest | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06086327 | Jun 2023 → Dec 2024 | thymoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT05093335 | Oct 2021 → Oct 2027 expected | Erdheim-Chester disease, histiocytic and dendritic cell neoplasm, non-Hodgkin lymphoma, plasma cell myeloma +1 | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 0 | NCT05364177 | Aug 2021 → Aug 2024 | plasma cell myeloma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT04504526 | Aug 2020 → Dec 2024 | leukemia, plasma cell myeloma | First Affiliated Hospital of Fujian Medical University | Unknown | No outcome recorded |
| Phase 0 | NCT03436342 | Jun 2019 → Mar 2020 | plasma cell myeloma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT03335670 | Nov 2017 → Dec 2029 expected | neuroendocrine neoplasm | Yusuf Menda | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07350707 | Jun 2023 → Mar 2026 overdue | Cushing syndrome | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT06246357 | Sep 2024 → Dec 2027 expected | Cushing syndrome, hyperaldosteronism | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT06478875 | Jun 2024 → Jun 2026 overdue | primary aldosteronism | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05321862 | Mar → May 2023 | plasma cell myeloma | Nantes University Hospital | Withdrawn | No outcome recorded |
| Phase 2 | NCT05222269 | Oct 2022 → Jan 2023 | central nervous system non-hodgkin lymphoma | Pentixapharm AG | Terminated | No outcome recorded |
| Phase 2 | NCT04561492 | Sep 2021 → Dec 2029 expected | plasma cell myeloma | Nantes University Hospital | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06125028 | May 2024 → Jul 2025 | marginal zone lymphoma | Pentixapharm AG | Terminated | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06871176 | Apr 2025 → Mar 2028 expected | plasma cell myeloma | University Health Network, Toronto | Recruiting | No outcome recorded |
| — | NCT05255926 | Mar 2022 → Dec 2026 expected | hematopoietic and lymphoid cell neoplasm | Zhongnan Hospital | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (68)Ga-Pentixafor | “Thus our study is going to investigate the value of 68Ga-pentixafor-PET/CT for the diagnosis，differentiation and pretherapeutic evaluation of CXCR4 expression in lymphoma.” NCT03436342 ↗10“Chemokine receptor-4 targeted PET/CT with (68)Ga-Pentixafor in assessment of newly diagnosed multiple myeloma: comparison to (18)F-FDG PET/CT.” PMID 31776631 ↗ Nov 2019 “68Ga Pentixafor is a radiolabeled cyclic pentapeptide with high affinity for CXCR4 receptor” NCT03335670 ↗ |
| Known as | 68Ga-PTF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05222269 ↗ |
| Known as | [(68)Ga]Ga-Pentixafor | “Reduced splenic uptake of [(68)Ga]Ga-Pentixafor following first-line chemotherapy is associated with poor prognosis in patients with newly diagnosed multiple myeloma.” PMID 40540129 ↗ Jun 2025 |
| Known as | PentixaFor | “PentixaFor radiolabeled with 68Gallium (68Ga) is a radiopharmaceutical targeting the CXC chemokine receptor 4 (CXCR4) receptor.” NCT06478875 ↗ |
| Modality | Peptide | “68Ga Pentixafor is a radiolabeled cyclic pentapeptide” NCT03335670 ↗ |
| Route | Intravenous | “administered intravenously” NCT03335670 ↗ |
| Target | CXCR4 | “Chemokine receptor CXCR4 was expressed in MM and lymphoma cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique” NCT03436342 ↗ |